EP2195002A4 - ERYTHROPOETIN RECEPTOR PEPTIDE FORMULATIONS AND USES - Google Patents

ERYTHROPOETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

Info

Publication number
EP2195002A4
EP2195002A4 EP08796513A EP08796513A EP2195002A4 EP 2195002 A4 EP2195002 A4 EP 2195002A4 EP 08796513 A EP08796513 A EP 08796513A EP 08796513 A EP08796513 A EP 08796513A EP 2195002 A4 EP2195002 A4 EP 2195002A4
Authority
EP
European Patent Office
Prior art keywords
erythropoietin receptor
receptor peptide
peptide formulations
formulations
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08796513A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2195002A1 (en
Inventor
Anne-Marie Duliege
Richard Stead
Kerstin Leuther
Kathryn Wynne Woodburn
Robert Barnett Naso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Inc
Original Assignee
Affymax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Inc filed Critical Affymax Inc
Publication of EP2195002A1 publication Critical patent/EP2195002A1/en
Publication of EP2195002A4 publication Critical patent/EP2195002A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP08796513A 2007-08-22 2008-07-23 ERYTHROPOETIN RECEPTOR PEPTIDE FORMULATIONS AND USES Withdrawn EP2195002A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95739607P 2007-08-22 2007-08-22
US98975807P 2007-11-21 2007-11-21
PCT/US2008/070943 WO2009025958A1 (en) 2007-08-22 2008-07-23 Erythropoietin rceptor peptide formulations and uses

Publications (2)

Publication Number Publication Date
EP2195002A1 EP2195002A1 (en) 2010-06-16
EP2195002A4 true EP2195002A4 (en) 2011-09-07

Family

ID=40194013

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08796513A Withdrawn EP2195002A4 (en) 2007-08-22 2008-07-23 ERYTHROPOETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

Country Status (3)

Country Link
EP (1) EP2195002A4 (enExample)
JP (2) JP2010536858A (enExample)
WO (2) WO2009025958A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422338B2 (en) 2011-05-19 2016-08-23 Epodose Llc Compounds that bind to the erythropoietin receptor
WO2015183545A1 (en) * 2014-05-28 2015-12-03 The Board Of Regents Of The University Of Texas System Novel compounds supports hematopoietic stem cells and red blood cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101606A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006133144A2 (en) * 2005-06-03 2006-12-14 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070027074A1 (en) * 2003-05-12 2007-02-01 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8343953B2 (en) * 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101606A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20070027074A1 (en) * 2003-05-12 2007-02-01 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006133144A2 (en) * 2005-06-03 2006-12-14 Affymax, Inc. Erythropoietin receptor peptide formulations and uses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FAN ET AL: "Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 34, no. 10, 1 October 2006 (2006-10-01), pages 1303 - 1311, XP005656813, ISSN: 0301-472X *
GLASPY J A: "THE DEVELOPMENT OF ERYTHROPOIETIC AGENTS IN ONCOLOGY", EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 3, 1 January 2005 (2005-01-01), pages 553 - 567, XP008074550, ISSN: 1472-8214 *
REDDY G K ET AL: "Preliminary results of a phase II dose-finding study of subcutaneous Hematide(TM) in patients with cancer receiving chemotherapy", SUPPORTIVE CANCER THERAPY 200701 US, vol. 4, no. 2, January 2007 (2007-01-01), pages 74 - 75, XP001539117, ISSN: 1543-2912 *
See also references of WO2009025958A1 *
WOODBURN ET AL: "Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 35, no. 8, 26 July 2007 (2007-07-26), pages 1201 - 1208, XP022171067, ISSN: 0301-472X *

Also Published As

Publication number Publication date
JP2010536857A (ja) 2010-12-02
WO2009025958A1 (en) 2009-02-26
WO2009025957A1 (en) 2009-02-26
JP2010536858A (ja) 2010-12-02
EP2195002A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
IL187354A0 (en) Erythropoietin receptor peptide formulations and uses
IL248128A0 (en) Stabilized receptor polypeptides and their use
IL203173A (en) Cationic peptides and preparations containing them
EP2225275A4 (en) PROTEIN FORMULATION
GB0712670D0 (en) Isolated peptides and uses thereof
HRP20130109T1 (en) Caspofungin formulations
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
GB0702020D0 (en) Peptides and their use
ZA200908969B (en) Formulations
GB0708376D0 (en) Novel polypeptides and uses thereof
GB0809979D0 (en) Formulations
GB0723712D0 (en) Peptides
GB0711957D0 (en) Formulations
GB0702021D0 (en) Peptides and their use
GB0702022D0 (en) Peptides and their use
GB0810232D0 (en) Formulations
EP2123666A4 (en) PEPTIDE
IL211407A0 (en) Controlled-released peptide formulations
EP2195002A4 (en) ERYTHROPOETIN RECEPTOR PEPTIDE FORMULATIONS AND USES
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
IL207174A0 (en) Peptides, compositions, and uses thereof
GB0703945D0 (en) Peptide
GB0705179D0 (en) Formulations
GB0710813D0 (en) Peptides and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110808

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/06 20060101ALI20110802BHEP

Ipc: C07K 14/505 20060101ALI20110802BHEP

Ipc: A61K 47/48 20060101ALI20110802BHEP

Ipc: A61K 38/17 20060101ALI20110802BHEP

Ipc: A61K 38/16 20060101AFI20110802BHEP

17Q First examination report despatched

Effective date: 20140203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140614